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ABSTRACT
Glioblastoma, one of the most aggressive forms of brain cancer, is featured by high 
tumor cell motility and invasiveness, which not only fuel tumor infiltration, but also 
enable escape from surgical or other clinical interventions. Thus, better understanding 
of how these malignant traits are controlled will be key to the discovery of novel 
biomarkers and therapies against this deadly disease. Tetraspanin CD151 and its 
associated a3β1 integrin have been implicated in facilitating tumor progression across 
multiple cancer types. How these adhesion molecules are involved in the progression 
of glioblastoma, however, remains largely unclear.Here, we examined an in-house 
tissue microarray-based cohort of 96 patient biopsies and TCGA dataset to evaluate 
the clinical significance of CD151 and a3β1 integrin. Functional and signaling analyses 
were also conducted to understand how these molecules promote the aggressiveness 
of glioblastoma at molecular and cellular levels. Results from our analyses showed that 
CD151 and a3 integrin were significantly elevated in glioblastomas at both protein and 
mRNA levels, and exhibited strong inverse correlation with patient survival (p < 0.006). 
These adhesion molecules also formed tight protein complexes and synergized with 
EGF/EGFR to accelerate tumor cell motility and invasion. Furthermore, disruption of 
such complexes enhanced the survival of tumor-bearing mice in a xenograft model, and 
impaired activation of FAK and small GTPases. Also, knockdown- or pharmacological 
agent-based attenuation of EGFR, FAK or Graf (ARHGAP26)/small GTPase-mediated 
pathways markedly mitigated the aggressiveness of glioblastoma cells. Collectively, 
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our findings provide clinical, molecular and cellular evidence of CD151-a3β1 integrin 
complexes as promising prognostic biomarkers and therapeutic targets for glioblastoma.
INTRODUCTION
Glioblastomas, grade IV gliomas by World Health 
Organization (WHO) classification, belong to one of 
the most aggressive types of brain cancer [1]. Current 
therapeutic management of glioblastomas involves 
surgical resection and adjuvant chemoradiation. Despite 
advances made in imaging and treatment modalities, 
the prognosis of glioblastoma remains very dismal with 
five-year patient survival as low as 3% [1]. This fatal type 
of brain cancer is characterized by tumor cells with highly 
motile and invasive capacities [2]. As such, glioblastoma 
is considered an infiltrating disease with a strong tendency 
to escape surgical or other therapeutic treatments [1].
The progression and recurrence of glioblastoma 
has been strongly linked to the activation of receptor 
tyrosine kinases (RTKs) and their signaling pathways 
[3]. In particular, the majority of glioblastomas exhibit 
activated signaling of epidermal growth factor receptor 
(EGFR), which occurs through gene amplification, 
activating mutations, and/or receptor overexpression 
[4]. Aside from promoting cell proliferation, EGFR 
signaling drives the motility and invasiveness of 
glioblastoma cells. Unfortunately, the clinical efficacy 
of EGFR-specific inhibitors in glioblastoma have fallen 
below expectations [5].
There is growing evidence that the malignancy of 
glioblastoma is strongly promoted by integrins, a family of 
heterodimeric receptors. This class of adhesion molecules 
supports cell-extracellular matrix (ECM) interactions, 
thereby permitting tumor cell migration and invasion [6]. 
As members of the integrin family, the laminin-binding 
(LB) integrins, including α3β1, α6β1 and α6β4, are highly 
expressed in cultured glioblastoma cells [7–9] or a subset 
of CD133+ glioma stem cells [10]. They are also implicated 
in promoting the migration and invasion of glioblastoma 
cells [7, 11]. In contrast, several RGD-binding integrins, 
including α5β1 and αvβ3 integrins, appear to promote 
tumor cell survival and/or drug resistance of glioblastomas 
[12, 13]. These observations raise the likelihood that 
integrins, particularly LB integrins, are candidate 
regulators of glioblastoma malignancy, and may serve as 
biomarkers and/or therapeutic targets for this aggressive 
disease.
The pro-malignant function and signaling of 
LB integrins are coordinated by members of the 
tetraspanin family, including CD151, CD9, CD81, and 
CD82 [14–16]. Notably, tetraspanins form tight protein 
complexes with LB integrins on the cell surface through 
protein-protein or protein-lipid interactions [17–19]. 
However, only CD151 directly interacts with α subunits 
of LB integrins at their extracellular portions, in which it 
dictates integrin activation and signaling by influencing 
their lateral clustering on the cell surface [18, 20]. It is 
of no surprise that CD151 is frequently implicated in 
promoting tumor progression by enhancing either α3 or α6 
integrin-dependent cellular processes [11, 21, 22]. There is 
also evidence that CD151 mediates LB integrin-dependent 
activation of multiple signaling pathways [11]. In addition, 
there are reports of links between CD151 expression and 
tumor grade or patient survival for several cancer types. 
Together, these available observations implicate that, 
like its associated LB integrins, CD151 is a potential key 
player in the progression of glioblastoma. How CD151 
and its associated LB integrins are associated with the 
aggressiveness of glioblastoma, however, still remains 
largely unclear, particularly at the clinical, cellular, and 
signaling levels.
Here, we report clinical and functional analyses of 
CD151 and its associated α3 integrin in glioblastoma. We 
applied annotated tissue microarrays (TMAs) to evaluate 
the correlation between the expression of CD151 or α3β1 
integrin and clinicopathological parameters, including 
tumor grade, IDH1 mutation status, and patient survival. 
Additionally, we performed functional studies of multiple 
glioma cell lines to assess the impact of CD151 ablation 
on glioma aggressiveness, particularly regarding cell 
motility and invasiveness. Finally, signaling analyses 
were conducted to identify key effectors downstream 
of CD151-LB integrin complexes. Results from these 
analyses demonstrate that CD151 and α3β1 integrin are 
key drivers of glioblastoma aggressiveness, and serve as 
independent prognostic markers and promising therapeutic 
targets.
RESULTS
Clinical association between CD151 and glioma 
malignancy
To evaluate the clinical significance of CD151 in 
glioma malignancy, we carried out immunohistochemistry 
(IHC) analyses with a TMA containing 96 paraffin-
embedded patient glioma tissues. As shown in Fig. 1A, 
CD151 staining was primarily localized on the plasma 
membrane of tumor cells and detectable in the cytoplasm. 
The number of CD151-positive tumors in the glioblastoma 
group, that is, WHO grade IV gliomas, was more than two-
fold higher than their low-grade counterparts (Fig. 1B). 
To evaluate the clinical significance of aberrant CD151 
expression, the patient cohort was divided into CD151-
low (<15% cells positive) and CD151–high groups (≥15% 
cells positive), as determined by Cutoff Finder (http://
molpath.charite.de/cutoff/index.jsp) [23]. Our data showed 
that patients belonging to the CD151-high group had 
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Figure 1: Relationship between CD151, WHO tumor grade, patient survival, and IDH1 gene status in a TMA-based 
glioma patient cohort. TMAs harboring 96 patient glioma tissues were subjected to H&E staining and IHC analyses of the CD151 
protein. A. Representative images of H&E staining (a, c, e & g) and corresponding CD151 antibody staining (b, d, f & h) of glioma 
tissues. B. CD151-positive staining (by percentage) versus tumor grade. P values indicated, *: p < 0.05; **: p < 0.01; ***: p < 0.001.  
(Continued )
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Figure 1: (Continued ) C. Correlation between CD151 expression and overall patient survival (OS); *, p < 0.05. Data shown for analyses of 
patient cohorts consisting of (a) WHO grade II-IV gliomas or (b) grade III-IV gliomas or (c) only IV gliomas, i.e., glioblastoma. D. Correlation 
between CD151 and status of IDH1 gene from our TMA-based patient cohort (left and middle panels) or TCGA glioblastoma samples 
(right panel). For B-D, an in-house TMA-based cohort was stratified into CD151-low and high groups based on IHC staining of CD151 and 
corresponding sample sizes indicated. The correlation between CD151 expression and patient survival was evaluated by the Log-rank test. 
E. Multi-variant analyses of CD151 as an independent prognostic factor of gliomas. Independent prognostic factors were determined by Cox 
proportional hazards analysis of an in-house TMA-based patient cohort (n = 88). TMZ, temozolomide. CI, confidence interval. Scale bar: 50 μm.
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poorer survival than their counterparts, regardless of how 
patient samples were pooled by tumor grade (Fig. 1C). 
A similar trend was also detected from our analyses of a 
commercial glioma TMA (data not shown).
Because IDH1 gene status is a powerful prognostic 
indicator for infiltrative gliomas [24], we also evaluated 
the relationship between its mutation status and CD151 
expression in our patient cohort. As shown in Fig. 1D, 
CD151 protein was significantly lower in gliomas with 
mutant IDH1. A similar trend was detected for CD151 
mRNA in The Cancer Genome Atlas (TCGA) glioblastoma 
dataset. Importantly, a multivariate analysis of our patient 
cohort showed that elevated CD151 expression was a better 
independent adverse prognostic marker, compared to patient 
age, IDH1 status or the treatment with temozolomide, a 
standard chemotherapeutic agent (Fig. 1E). Together, these 
data demonstrate a strong association between CD151 
expression and glioma aggressiveness.
CD151 promotes glioma cell motility 
and invasion
Next, we conducted in vitro analyses to test if 
CD151 functionally contributed to the aggressiveness 
of gliomas as suggested by our clinical analyses 
(Fig. 1). Our FACS analyses indicated that CD151 and 
LB integrins were highly expressed across a panel of 
glioblastoma cell lines (Supplementary Fig. S1). The 
strong expression of other tetraspanins, including CD9 
and CD81, was also detected, consistent with a recent 
report [25]. According to our Matrigel-based invasion 
assay, these tumor cell lines exhibited a wide range of 
variation in invasiveness (Fig. 2A). In particular, the 
invasive capabilities of LN428, LN308 and LN229 
lines increased by 3.5- to 5-fold upon EGF stimulation, 
consistent with the strong pro-malignant function of 
EGFR in glioblastomas [26, 27]. Because CD151 or its 
associated LB integrins have been shown to functionally 
collaborate with EGFR in other cancer types [15, 28], 
these highly EGF-responsive cell lines were adopted for 
subsequent functional analyses.
In the three cell lines most sensitive to EGF (LN229, 
LN308, and LN428), CD151 knockdown led to a 2- to 
7-fold decrease in the number of tumor cells invading 
through the Matrigel after EGF stimulation (Fig. 2B). Also, 
EGF-stimulated random cell motility was mostly abolished 
upon CD151 ablation when LN229 cells were engaged with 
laminin-5, i.e., laminin 332, but not fibronectin (Fig. 2C). 
However, CD151 knockdown had only minimal effect on the 
proliferation of glioma cells (data not shown). In line with 
these in vitro observations, CD151 knockdown extended 
the survival of tumor-bearing mice with orthotopic LN229 
glioblastoma xenografts (Fig. 2D, p < 0.05), even though 
minimal change occurred in tumor growth. These in vitro 
and ex vivo observations demonstrate that CD151 promotes 
glioblastoma progression by promoting tumor cell motility 
and invasiveness, rather than impacting cell proliferation or 
tumor growth.
Functional and clinical links of CD151-associated 
α3β1 integrin to glioblastoma malignancy
Tetraspanin CD151 is implicated in mediating diverse 
physiological and pathological processes by impacting the 
function or signaling of its associated protein complexes, 
instead of directly interacting with signaling molecules 
[17, 28]. Such complexes are also readily detected by the 
abilities of integrins and tetraspanin molecules to incorporate 
palmitate and form tetraspanin-enriched membrane 
microdomains (TEMs) [17]. Therefore, we conducted [3H]-
palmitate labeling and co-immunoprecipitation analyses 
of multiple glioblastoma cell lines under 1.0% Brij96 
condition. Our data showed that CD151 was present in the 
protein complexes of α3 and α6 integrins in multiple glioma 
cell lines (Fig. 3A). In addition, several other tetraspanins, 
including CD9, CD81 and CD82, appeared to exist in the 
complexes. The profile of these labeled proteins was also 
consistent with our prior studies [16, 29], and supported by 
the surface expression of these molecules from our FACS 
analyses (Supplementary Fig. S1).
Functional analyses were subsequently performed to 
evaluate the contribution of such protein complexes to the 
aggressiveness of gliomas. As shown in Fig. 3B, knockdown 
of α3 or α6 integrin was as effective as CD151 ablation in 
inhibiting EGF-induced invasion of LN229 cells. In contrast, 
CD9 knockdown enhanced both basal and EGF-induced 
invasion of glioma cells, consistent with its anti-invasive role 
as shown in prior studies [25, 28]. In further support of these 
observations, we found that the stable knockdown of β1 
integrin led to a marked inhibition in the invasion of LN229 
cells (Fig. 3C). Together, these data illustrate that CD151 
and its associated LB integrins form protein complexes and 
cooperate to promote the invasiveness of glioblastomas.
Next, analyses of clinical samples were conducted 
to evaluate the link of CD151-associated α3 integrin to the 
malignancy of gliomas. As shown in Fig. 4A–B, expression 
of α3 integrin was detectable in plasma membrane and 
cytoplasmic compartments of tumor cells, and was markedly 
elevated in high-grade gliomas including glioblastomas. 
Again, by using 15% cells being α3 integrin-positive as a 
cutoff value, we found that elevated expression of α3 integrin 
was strongly correlated with poor patient survival (p < 0.006) 
(Fig. 4C). There was also a significant negative correlation 
between the level of this integrin and the mutation status of 
IDH1 (Fig. 4D). Protein expression of CD151 and α3 integrin 
were strongly correlated in our patient cohort (slope = 11.2 ± 
0.93, R2 = 0.58, p < 0.0001) (Fig. 4E). In addition, a similar 
association occurred at the mRNA level, according to our 
analyses of the TCGA glioma dataset (Fig. 4E). Together, 
our analyses of two independent clinical cohorts consistently 
suggest that CD151 and α3 integrin act together to promote 
the aggressiveness of gliomas.
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Figure 2: A role of CD151 in EGF-induced glioblastoma cell motility, invasion, and ex vivo tumor formation. A. EGF-
stimulated invasiveness of cultured glioblastoma cell lines. Glioblastoma cell lines including LN827, LN428, LN308, LN229, U87 and LN373 
were subjected to an invasion assay with respect to the presence and absence of EGF. 1.0 × 105 tumor cells were placed on the top of a Matrigel-
coated insert in a 24-well plate and allowed to invade for 17–20 hrs before being fixed. Number of invaded cells is shown (mean ± SEM, n = 3).  
(Continued )
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Figure 2: (Continued ) B. Effect of CD151 knockdown (KD) on the invasion of LN308 and LN229 cells (fold change ± SEM, n = 3). 
The efficiency of stable knockdown of CD151 was assessed by FACS analyses (see Supplementary Fig. S2). C. Effect of CD151 KD on 
glioma cell motility. Random cell motility was measured for LN229 cells with or without CD151 KD. The analyses were conducted in 
triplicate and average distance traveled by individual cells were estimated. A total of 25–35 individual cells per treatment were tracked. For 
A-C, EGF: 10 ng/ml. D. Xenograft analyses of CD151 ablation on tumor growth. Mice injected with control or CD151 knockdown LN229 
cells at 10 animals per group monitored over the indicated periods of times. (a) Survival curve of tumor-bearing mice. The p-value was 
obtained by Log-rank test; (b) Change in the bioluminescence of injected mice.
CD151-α3β1 integrin complexes drive tumor cell 
motility and invasion via FAK activation
Recent studies have implicated that FAK is a 
putative driver of glioma malignancy and acts downstream 
of CD151-integrin complexes [15, 28]. Hence, we 
examined the signaling link of FAK activation to CD151-
integrin complex-mediated glioma aggressiveness. Our 
data showed that the stable knockdown of CD151 caused 
a delay or decrease in the phosphorylation of FAK-Y397 
residue induced by the engagement of α3β1 integrin and 
its physiological ligand, laminin-5, during the transient 
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Figure 3: The pro-invasive function of CD151-associated protein complexes in glioblastoma cells. A. Co-immunoprecipitation 
of CD151 and LB integrins. Lysates of [3H]-palmitate-labeled glioma tumor cells were subjected to immunoprecipitation with the indicated 
antibodies, followed by radiographic detection. Left panel, short exposure; right panel, long exposure. B. Impact of disrupting CD151, 
and its associated integrins and tetraspanin molecules on the invasion of glioma cells. LN229 cells were treated with scramble (control) or 
siRNA against CD9, CD151, α3 and α6 integrins. Fold changes were calculated relative to the number of invaded cells in the group treated 
with control siRNA in the absence of EGF stimulation. 
(Continued )
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spreading of either LN229 or LN308 cells (Fig. 5A). In 
addition, FAK knockdown reduced the EGF-induced 
invasion of LN229 and LN308 cells by 2.3- to 3.5-fold 
(Fig. 5B), respectively. In line with these observations, 
EGF-induced cell motility was also markedly impaired 
when FAK was inhibited by the use of a small molecule-
based inhibitor, TAE226 [30]. Such inhibition was 
nearly equally effective as CD151 knockdown (Fig. 5C). 
Moreover, the involvement of EGFR in the motility of 
glioma cells was independently validated by our analyses 
with two clinically relevant EGFR inhibitors, lapatinib/
Tykerb and gefitinib/Iressa (Fig. 5D). Taken together, 
these results illustrate that FAK promotes the aggressive 
traits of gliomas by acting downstream of CD151-integrin 
complexes and EGFR.
Graf (ARHGAP26) as a key downstream effector 
of CD151-α3β1 integrin complex signaling
Integrins have recently been implicated in 
promoting the motility of glioma cells via activation of 
multiple small GTPases including Rac1 and Cdc42 [31, 
32]. Thus, we sought to determine whether a similar link 
existed in glioma cells. Our data showed that CD151 
knockdown markedly impaired the activation of Rac1 
or Cdc42 GTPases upon engagement of α3 integrin with 
laminin-5 in LN229 or LN308 cells (Fig. 6A). Next, we 
sought to identify which specific GDP/GTP exchange 
factors or RhoGAPs acted downstream of CD151-integrin 
complexes. As shown in Fig. 6B, disruption of DOCK180 
impaired motility of LN229 cells on fibronectin but not 
laminin-5 substrate. A similar effect was found when 
ELMO1, another motility-related adaptor molecule 
strongly implicated in the aggressiveness of gliomas [33], 
was knocked down (Fig. 6C). However, only disruption 
of Graf (ARHGAP26) led to a marked decrease in the 
motility of LN229 cells on laminin-5, regardless of 
EGF stimulation (Fig. 6C). Together, these observations 
indicate a crucial role of the Graf (ARHGAP26)/Rac1/
Cdc42 axis, not DOCK180 or ELMO1, in CD151-α3 
integrin complex-mediated signaling in glioblastoma.
DISCUSSION
Results from our studies support a close link 
between CD151-α3β1 integrin complexes and the 
aggressiveness of glioblastomas. Our analyses of TMA-
based glioma patient cohort as well as TCGA glioma 
dataset consistently indicate that the expression of CD151 
or α3β1 integrin is strongly correlated with tumor grade, 
IDH1 gene status, and patient survival. Our biochemical 
analyses reveal the presence of CD151-α3β1 integrin 
complexes in glioblastoma cells. Disruption of CD151 or 
α3β1 integrin markedly impairs EGF/EGFR-evoked tumor 
cell motility and invasiveness. At the signaling level, 
CD151-α3β1 integrin complexes cooperate with EGFR 
to activate FAK- and Graf (ARHGAP26)/Rac1/Cdc42 
Figure 3: (Continued ) C. Effect of stable knockdown of β1 integrin on the invasion of LN229 cells. EGF: 10 ng/ml. B-C The efficiency 
of tetraspanin or integrin knockdown was estimated by immunoblotting or FACS analysis (see Supplementary Fig. S3, panels A-B).
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axis-mediated pathways. Together, these findings provide 
strong clinical, cellular and molecular evidence that 
CD151-α3β1 integrin complexes and associated pathways 
are crucial players in the progression of glioblastoma or 
other malignant gliomas (Fig. 6D).
Aberrant expression of CD151 and α3β1 integrin 
as independent prognostic factors
The current study provides strong clinical evidence 
for the close link between CD151 or its associated α3β1 
integrin and the malignancy of human glioblastoma. 
Our TMA-based analyses reveal significant correlation 
between CD151 or its associated α3β1 integrin and 
tumor grade, patient survival, and IDH1 gene status 
(Figs. 1, 4). These results are also in accord with recent 
reports of CD151 expression in glioblastomas [34, 35]. 
Moreover, our data indicate a significant concordance in 
the expression of CD151 and α3β1 integrin in our patient 
cohort and TCGA gliomas (Fig. 4E). As such, our findings 
support CD151 and α3β1 integrin as potential biomarkers 
for glioblastoma.
It is of clinical significance to know how expression 
of CD151 or α3β1 integrin is markedly elevated in 
glioblastomas at both the mRNA and protein levels. Based 
on prior biochemical analyses, the increase in CD151 
protein is potentially attributable to the simultaneous 
elevation in α3 integrin [18]. However, it is still unclear 
as to the mechanism of CD151 mRNA upregulation in 
glioblastomas. Our analyses of TCGA glioblastomas 
Figure 4: Relationship between α3 integrin, WHO tumor grade, IDH1 gene status, patient survival and CD151 
expression in a TMA-based glioma patient cohort and TCGA glioblastomas. A. Representative images of H&E 
(a, c, e, g) and IHC staining (b, d, f, h) of an in-house glioma TMA as described in Figure 1. IHC analyses were conducted with a 
polyclonal antibody against α3 integrin. a-b, grade II; c-d grade II; e-f, grade III; g-h, grade IV or glioblastoma. P values indicated.  
(Continued )
Oncotarget29685www.impactjournals.com/oncotarget
Figure 4: (Continued ) B. A plot of percentages of α3 integrin-positive staining versus tumor grade. P values are indicated (*p < 0.05; 
**p < 0.01; ***p < 0.001). C. Association of α3 integrin and overall patient survival (OS) in WHO grade III-IV gliomas. The patient cohort 
was divided into low and high α3 integrin expression groups. The cutoff was at ≥ 3 IHC staining of α3 integrin. The significance of the 
correlation between α3 integrin and patient’s survival was assessed by the Log-rank test. D. The association between CD151 expression and 
status of IDH1 gene from IHC or TCGA database analyses. E. Correlation between CD151 and α3 integrin expression in the TMA cohort 
of grade II-IV gliomas at protein level (left panel) or at mRNA level (right panel). The mRNA expression of these genes was obtained in 
the external TCGA glioblastomas dataset. Sample sizes indicated. Scale bar: 50 μm.
reveal minimal change in the copy number of CD151 or α3 
integrin gene (data not shown), implicating a mechanism 
other than gene amplification or copy gain. Meanwhile, 
there is evidence that CD151 expression in gliomas is 
regulated by micro-RNAs or epigenetic regulation [34, 
36]. In particular, mutation of IDH1 gene in gliomas has 
been shown to influence the methylation of a number of 
pro-malignant genes [3, 37], and is strongly associated 
with CD151 expression in our patient cohort (Fig. 1D). 
Thus, there is a likelihood that the aberrant expression of 
CD151 or α3β1 integrin in high-grade gliomas may result 
from epigenetic regulation.
Functional contribution of CD151 and α3β1 
integrin to glioblastoma malignancy
Although the RGD-based integrins, such as 
α5β1 integrin, are shown to promote survival and drug 
resistance of glioblastoma cells [12, 38], disruption of 
CD151 or α3β1 integrin appears to have minimal influence 
on the proliferation or survival of glioblastoma cells (data 
not shown). Rather, CD151 and α3β1 integrin drive the 
aggressiveness of glioblastoma by accelerating tumor cell 
motility and invasiveness (Figs. 2, 5, 6). These findings 
are also in line with recent functional studies of these 
molecules in glioblastomas [7–9, 39]. Given the high 
expression of multiple laminin isoforms in glioblastoma 
cells [8, 9, 40], CD151-α3β1 integrin complexes may 
act in an autocrine fashion. This notion is also supported 
by recent observations of α3β1 integrin function across 
multiple cancer types [41]. Moreover, because normal 
brain tissues are highly enriched in laminins [42], the 
pro-malignant roles of CD151-α3β1 integrin complexes 
in glioblastomas are likely strengthened by the tumor 
microenvironments.
Our data also implicate that the impact of CD151-
α3β1 integrin complexes on the malignant behaviors of 
glioblastomas may occur in the context of TEMs. Notably, 
functional loss of tetraspanin CD9 led to a marked 
increase in EGF-stimulated tumor cell invasion, consistent 
with recent analyses of CD81 and its associated EWI-2 
protein complexes in gliomas [25]. Intriguingly, CD151 
knockdown in multiple glioblastoma lines had minimal 
effect on the surface expression of its associated partners, 
as determined by our FACS analyses (Supplementary 
Fig. S2). Perhaps, CD151 promotes the clustering of its 
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Figure 5: Activation of FAK in glioma cells by CD151-α3β1 integrin complexes and their crosstalk with EGFR. A. Effect 
of CD151 ablation on integrin-dependent phosphorylation of FAK-Y397 residue. LN229 or LN308 cells with or without stable CD151 KD 
were transiently placed onto laminin-5 substrate for the indicated periods of time, followed by lysing in RIPA buffer and immunoblotting. Top 
panel, immunoblotting of total or phosphorylated FAK. Bottom panel, ratios of FAK-Y397/Total FAK proteins determined by densitometry. 
B. The impact of FAK knockdown on the invasion of either LN229 or LN308 glioma cells. FAK was knocked down via siRNA and 
confirmed by immunoblotting (see Supplementary Fig. S3, panel C). 
(Continued )
associated integrin molecules on the cell surface [20, 28]. 
How CD151 and CD9 molecules within the same protein 
complexes or TEM confer opposing cellular or signaling 
functions, however, still remains a mystery.
Of note, CD151 may also drive glioblastoma 
malignancy by affecting the stemness property of glioma 
cells. This tetraspanin has recently been linked to the 
dynamics of tumor-initiating or progenitors cells [43, 44]. 
Also, CD151-associated α3 and α6 integrins are shown 
to enhance the aggressive behaviors of cancer stem cells 
[7, 10]. Thus, identification of a stem cell-related link will 
shed new light on the importance of CD151-LB integrin 
complexes or associated TEMs in glioblastoma malignancy.
Signaling role of CD151-α3β1 integrin complexes 
in glioblastomas
The strong cooperation or synergy between CD151-
LB integrins complexes and EGFR in glioblastomas 
revealed by our study (Figs. 3–6) is of high translational 
significance, as aberrant activation of this RTK occurs in 
>70% gliomas [4]. This type of signaling crosstalk is also 
consistent with our recent analyses of CD151 function 
in other malignancies, including breast and skin cancers 
[21, 28]. In addition, our observation of the activation 
of FAK as reflected by the enhanced phosphorylation 
of Y397 residue upon the engagement of laminin-5 and 
CD151-integrin complexes is in line with the pro-
malignant role of this non-receptor tyrosine kinase in 
glioblastomas [45]. Beside the phosphorylation of Y397 
residue, FAK may convey CD151-integrin complex-
mediated signaling through the phosphorylation of Y925 
residue upon EGF stimulation [46, 47]. Furthermore, 
we found that CD151-α3β1 integrin complexes signal 
through Graf (ARHGAP26)/small GTPase-dependent 
pathways in glioblastoma cells (Fig. 6). In contrast to a 
prior report on ELMO1, a regulator of GTPase activation 
and glioma cell motility [33], our study suggest that 
the crosstalk between the CD151-integrin complexes 
and RTKs converge at ARHGAP26, consistent with its 
link to the EGFR-mediated cell motility and signaling 
[48]. Collectively, our data suggest that CD151-α3β1 
integrin complexes and EGFR converge at FAK and Graf 
(ARHGAR26) to drive the motility and invasiveness of 
glioblastoma.
The contribution of CD151 and associated LB 
integrins to glioma aggressiveness may not be completely 
dependent on their crosstalk with the EGFR pathway. 
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Figure 5: (Continued ) C–D. The impact of FAK or EGFR inhibition on EGF-mediated random tumor cell motility in control and 
CD151 KD LN229 cells. Inhibition of FAK and EGFR was carried out by using TAE226 or Lapatinib or Gefitinib at 0.1 μM or 0.5 μM.
In fact, CD151 and LB integrins have been shown to 
collaborate with multiple oncogenic RTKs (e.g., c-Met 
and ErbB2) or Ras/MAPK pathways [15, 28, 49] or Myc-
driven network [50]. As these oncogenic events frequently 
occur in glioblastoma [26, 27, 51], the cooperation 
between CD151-α3β1 integrin complexes and EGFR 
detected in the current study may only reflect part of broad 
contributions of such complexes to the aggressiveness of 
such disease. However, it is unlikely that the signaling 
effect of CD151–integrin complex detected in the current 
study is attributed to their impact on the EGFR activation, 
particularly its autophosphorylation, according to our 
recent studies [15, 52].
It is worth noting that the pro-malignant function 
of CD151-integrin complexes in glioblastoma occurs 
in the context of cell-ECM interaction, consistent with 
prior studies in other cancer types [52, 53]. However, 
such adhesion molecules are also capable of suppressing 
tumorigenesis, particularly in the presence of intact cell-
cell contact or E-cadherin [54, 55].
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Implications of CD151-α3β1 integrin complexes 
and associated pathways as therapeutic targets
Results from the present study strongly support 
the prognostic and therapeutic potential of CD151-
α3β1 integrin complexes and their associated pathways 
for glioblastoma. Experimentally, the pro-malignant 
roles of CD151 or α3β1 integrin are readily disrupted 
by administration of function-blocking monoclonal 
antibodies, such as 1A5 or Tsr151 for CD151, and IIF5 
or P1B5 for α3 integrin [21]. The functional disruption 
of these molecules is also achievable through inhibition 
of downstream signaling, such as FAK activation (Fig. 5). 
Given the emerging link of these molecules to the 
Figure 6: A functional link between CD151-LB integrin complexes and the GRAF/Small GTPase signaling axis. A. Effect 
of CD151 ablation on integrin-dependent activation of small GTPase Rac1 and Cdc42 in LN229 and LN308 cells. Control and CD151 KD 
cell were detached and transiently engaged with laminin-5 substrate for the indicated periods of time, followed by lysing in RIPA buffer and 
immunoblotting. Top panel, immunoblotting of Rac1 in GTP-bound form or present in cell lysates. Bottom panel, indices of GTP-bound 
Rac1 protein determined by densitometry. 
(Continued )
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stemness of glioblastoma [7, 10], targeting CD151-LB 
integrin complexes may also provide an effective means 
against tumor recurrence.
In summary, our study demonstrates that CD151 
and its associated α3 integrin are markedly elevated in 
malignant gliomas, and synergize with EGFR-dependent 
signaling pathways to drive the aggressive behaviors of 
glioblastoma cells. As such, our findings provide crucial 
evidence of CD151-integrin complexes and associated 
pathways as prognostic markers and therapeutic targets 
for glioblastoma or other aggressive gliomas.
MATERIALS AND METHODS
Antibodies, reagents, and cell cultures
CD151 monoclonal antibodies include 5C11, 1A5 
and FITC-conjugated IIG5a (GeneTex, San Antonia, TX). 
Anti-CD9 monoclonal antibody MM2/57 (unconjugated 
and FITC conjugated) was from Biosource (San Diego, 
CA). The monoclonal antibodies to CD81 (M38) or 
integrin α2 (IIE10), α3 (X8), α6 (GÖH3), β1 (TS2/16), and 
β4 (3E1) were described elsewhere [15, 16]. Antibodies to 
FAK and Y397-phosphorylated FAK were obtained from 
Santa Cruz Biotechnology (Santa Cruz, CA). Antibodies to 
small GTPases (Rac1 and Cdc42) were obtained from Cell 
Signaling Technology (Danvers, MA). Small molecule-
based inhibitors against FAK (TAE226) or EGFR/ErbB2 
(lapatinib or gefitinib) were described in a prior study [15].
Antibodies used for IHC analyses of CD151 and 
α3 integrin were obtained from Leica Microsystems 
(Lawrenceville, GA) or prepared in-house [54]. IDH1 
mutation status was examined by using an anti-R132H 
IDH1 antibody (HistoBioTec, Miami Beach, FL). Human 
glioblastoma cell lines LN827, LN428 and LN308 were 
obtained from Dr. Erwin Van Meir (Emory University, 
Atlanta, GA) [56]. LN229, LN373, and U87 lines were 
purchased from ATCC (Manassas, VA). For xenograft 
Figure 6: (Continued ) B-C. Effect of DOCK180, ELMO1, and GRAF/ARHGAP26 knockdown on integrin-mediated 
motility of LN229 glioma cells. The average distance traveled by tumor cells was calculated. Values: mean ± SEM (n = 15). 
Efficiency of DOCK180, ELMO1, and GRAF/ARHGAP26 knockdown was assessed by immunoblotting (see Supplementary 
Figure S3, panels D-E). EGF: 10 ng/mL. D. A schematic illustration of a working model of CD151-α3β1 integrin complexes 
in glioblastoma.
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analysis, LN229 cells were engineered to express 
luciferase as previously described [57]. No authentication 
was conducted on all cell lines used in the current study. 
All cell lines were cultured in DMEM or RPMI-1640 
supplemented with 10% fetal bovine serum, 10 mmol/L 
HEPES, and antibiotics (Invitrogen, Carlsbad, CA). 
All cultures were maintained at 37°C in a humidified 
atmosphere of 5% CO2. EGF was obtained from UBI 
(Lake Placid, NY). Matrigel and fibronectin were obtained 
from BD Biosciences (San Jose, CA). Laminin-5 was 
prepared for the condition medium of A431 carcinoma 
cells as previously described [30].
Transient and stable knockdown of tetraspanins 
and integrins using siRNA and shRNA
For all transient knockdowns, on-target siRNAs 
were purchased from Dharmacon (Lafayette, CO) and 
delivered to tumor cells using Lipofectamine-2000 
(Invitrogen). For stable knockdown, human CD151 or 
β1 integrin oligos were cloned into lentivirus expression 
vector plenti-U6BX and verified by DNA sequencing and 
mutagenesis analyses as previously described [28]. The 
infected cells were sorted on flow cytometry by double 
sorting with GFP and with specific monoclonal antibodies 
for selection of stable CD151 or β1 integrin knockdown 
cell lines.
Cell sorting and FACS analyses
Cell sorting was carried out to obtain glioblastoma 
cell lines infected with lentivirus-expressing control or 
CD151-specific shRNA as previously described [28]. 
Virus-infected tumor cells were initially stained with 
anti-CD151 monoclonal antibodies (5C11) and APC-
conjugated secondary antibodies on ice, followed by two-
way sorting on flow cytometry at our local core facility. 
For FACS analyses of the expression of cell surface 
molecules, tumor cells were stained with the indicated 
primary monoclonal antibodies, followed by fluorescence-
conjugated secondary antibodies prior to analyses on flow 
cytometry. For each FACS analyses, a total of 5–10 × 
103 cells were analyzed and mean fluorescence intensity 
values were calculated.
Tumor cell motility, invasion, and 
proliferation assays
Analyses of random cell motility were conducted by 
imaging live tumor cells at 20 min intervals for 12 h with 
a Nikon Automated Eclipse Ti-E inverted microscope and 
an OKALAB incubator equipped with a heater and gas 
mixer constant at 37°C and 5% CO2. Nikon NIS-Elements 
Advanced Analysis Software was employed to estimate 
distance traveled by tumor cells as described in our prior 
study [15]. For analyses of tumor cell invasion, cells 
were detached using non-enzymatic EDTA-containing 
dissociation buffer (Life Technologies, Grand Island, NY). 
Cells were then suspended in serum-free DMEM with 
0.02% bovine serum albumin, and added to trans-well 
chambers containing 8-μm membranes pre-coated with 
Matrigel (BD Biosciences). Chamber bottoms contained 
serum-free medium with or without presence of 10 ng/mL 
EGF. After invasion through Matrigel (12–18 h, 37°C), 
membranes were washed, dried, fixed, and stained with 
Giemsa (Sigma-Aldrich, St. Louis, MO). Proliferation of 
human glioblastoma cells was evaluated by MTT assay. 
Fold changes were calculated relative to the control 
without the presence of a stimulant.
Immunoprecipitation, [3H]-palmitate labeling, 
and signaling assays, and immunoblot analyses
For metabolic labeling, siRNA-treated cells (80–90% 
confluent) were washed in PBS, serum starved (3–4 h), 
pulsed for 1–2 h in medium containing 0.2 to 0.3 mCi/mL 
[3H]-palmitic acid plus 5% dialyzed FBS, and then lysed 
in 1% Brij-96 for 5 h at 4oC. Immunoprecipitation 
and detection of [3H]-palmitate-labeled proteins were 
completed as previously described (12, 30, 31). To assess 
protein phosphorylation, cells were lysed in RIPA buffer 
containing 1% Triton X-100, 1% deoxycholate, and 
0.1% SDS.
For signaling analyses, cells were seeded onto 
6-well plates (2 × 105 cells per well) and starved overnight 
prior to stimulation. Cells were lysed in RIPA buffer 
supplemented with 1 mM Na3VO4, PMSF and protease 
inhibitor cocktail [30]. Protein concentrations were 
quantified by use of DC Protein Assay Kit (Bio-Rad, 
Hercules, CA). Then phosphorylated proteins were either 
immunoprecipitated and blotted with anti-phosphotyrosine 
antibody (4G10, UBI) or directly blotted in cell lysates 
using phospho-specific antibodies. Rac1 activation was 
assessed with a glutathione S-transferase (GST)-PBD pull-
down assay kit (UBI).
Immunoblotting or Western analyses were 
conducted by separating equal amounts of proteins on 
SDS-PAGE and transferring samples onto a nitrocellulose 
membrane prior to blotting detection with the indicated 
antibodies. For evaluation of the differences in protein 
expression, ratios of densitometry values of individual 
protein to β-actin were calculated. These values were 
subsequently divided by the smallest value within the 
group to obtain a fold change.
Tissue microarrays of glioblastomas and IHC 
analyses
A set of tissue microarrays (TMAs) were prepared 
in-house using archived formalin-fixed, paraffin-
embedded gliomas as previously described [45]. A total 
of 96 cases comprised the TMAs, including 9 WHO 
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grade II astrocytomas, 11 grade III astrocytomas, 12 
anaplastic grade III oligodendrogliomas, 16 grade II 
oligodendrogliomas, and 47 grade IV glioblastomas. 
A commercial TMA of glioblastomas was also purchased 
from US Biomax (Rockville, MD). IHC staining of 
paraffin-embedded TMAs was performed as previously 
described [45]. In brief, secondary antibodies were 
EnVision labeled polymer-HRP (horseradish peroxidase) 
anti-mouse or anti-rabbit as appropriate. Staining 
was visualized using 3, 3′-diaminobenzidine (DAB) 
chromogen (Dako, Copenhagen, CA). The TMAs stained 
with antibodies against CD151 were digitally quantified 
via ScanScope XT whole slide scanner, followed by 
analysis with Aperio Spectrum Version 11.2.0.780 
software. For technical reasons, the TMA cores stained 
with α3 integrin were difficult to reliably score digitally, 
so instead they were visually semi-quantified by C.H. 
on a relative scale from 0 to 3 (0 = negative, 1 = weak, 
2 = intermediate, 3 = strong).
For both digital and visual scoring, results from all 
3 cores were averaged together to produce a final score for 
a tumor. The scoring of immunostaining was evaluated on 
the basis of staining intensity and percentages of positively 
stained areas.
Tumor xenograft analyses
All animal experiments were carried out in 
accordance with protocols approved by the Institutional 
Animal Care and Use Committee at the Dana-Farber 
Cancer Institute (Boston, MA). Control or CD151 
knockdown LN229 were infected with luciferase-
expressing retrovirus, selected with G418 and 
subsequently verified for the expression of luciferase or 
CD151 by immunoblotting. For orthotopic analyses, the 
luciferase-expressing tumor cells were dissociated and 
resuspended in HBSS at a density of 1.0 × 105 cells/μL. 
A total of 2.0 μL of tumor cell mixture was injected into 
the striatum of immunocompromised nude mice in the 
position of 2 mm posterior to the bregma, 2 mm laterally, 
and 2 mm deep to the dura, as described in our prior study 
[57]. Changes in tumor sizes were determined on the basis 
of chemoluminescence intensity under a Xenogen imager. 
In the course of the study, all animals were euthanized at 
the onset of neurological symptoms or once moribund. For 
in vivo imaging, mice were anesthetized, given D-luciferin 
at 50 mg/mL by intraperitoneal (I.P.) injection (Xenogen, 
Alameda, CA), and imaged with the IVIS Imaging System 
(Xenogen) for 10–120 s, bin size 2. Data were normalized 
to bioluminescence at the initiation of treatment for each 
animal.
Statistical analysis
All experiments described in the study were 
independently repeated. Differences between groups were 
analyzed via two-tailed t-test or one-way ANOVA with 
post-hoc Dunn’s test, as appropriate. Correlation between 
CD151 and α3 integrin expression was measured via linear 
regression. Survival differences were compared via log-
rank (Mantel-Cox) test. Multivariate survival analysis was 
done via Cox proportional hazards survival regression. 
Statistical significance was reached when p < 0.05. All 
analyses were done via GraphPad software (La Jolla, 
CA), except for the Cox proportional hazards survival 
regression which was done using http://statpages.org/.
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